Israel - hebraisk - Ministry of Health

taro international ltd, israel - erlotinib as hydrochloride - טבליות מצופות פילם - erlotinib as hydrochloride 100 mg - erlotinib

Israel - hebraisk - Ministry of Health

taro international ltd, israel - erlotinib as hydrochloride - טבליות מצופות פילם - erlotinib as hydrochloride 150 mg - erlotinib

Israel - hebraisk - Ministry of Health

taro international ltd, israel - erlotinib as hydrochloride - טבליות מצופות פילם - erlotinib as hydrochloride 25 mg - erlotinib

Israel - hebraisk - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - erlotinib hydrochloride - טבליות מצופות פילם - erlotinib hydrochloride 100 mg - erlotinib

Israel - hebraisk - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - erlotinib as hydrochloride - טבליות מצופות פילם - erlotinib as hydrochloride 150 mg - erlotinib

Israel - hebraisk - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - erlotinib hydrochloride - טבליות מצופות פילם - erlotinib hydrochloride 25 mg - erlotinib

Israel - hebraisk - Ministry of Health

teva israel ltd - erlotinib as hydrochloride - טבליות מצופות פילם - erlotinib as hydrochloride 25 mg - erlotinib

Israel - hebraisk - Ministry of Health

sam-on ltd - nicotinic acid; pepsin; sodium glycerophosphate - טיפות - pepsin 0.6 %w/v; nicotinic acid 0.2 %w/v; sodium glycerophosphate 0.8 %w/v - pepsin and acid preparations - pepsin and acid preparations - treatment of constipation and flatulence.

Israel - hebraisk - Ministry of Health

abbott medical laboratories ltd - niacin 500 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n

Israel - hebraisk - Ministry of Health

abbott medical laboratories ltd - niacin 750 mg - film coated tablets - extended release - nicotinic acid - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.niaspan is indicated to reduce elevated tc, ldl-c, apo b and tg levels, and to increase hdl-c in patients with primary hyperlipidemia and mixed dyslipidemia. 2.niaspan in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with niaspan, simvastatin, or lovastatin monotherapy is considered inadequate. 3.in patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.in patients with a history of coronary artery disease (cad) and hyperlipidemia, n